JP2002504095A - Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン - Google Patents

Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン

Info

Publication number
JP2002504095A
JP2002504095A JP54297198A JP54297198A JP2002504095A JP 2002504095 A JP2002504095 A JP 2002504095A JP 54297198 A JP54297198 A JP 54297198A JP 54297198 A JP54297198 A JP 54297198A JP 2002504095 A JP2002504095 A JP 2002504095A
Authority
JP
Japan
Prior art keywords
dihydro
quinazolinone
trifluoromethyl
substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54297198A
Other languages
English (en)
Japanese (ja)
Inventor
コルベット，ジェフリー，ダブリュ．
コ，スー，サン．
Original Assignee
デュポン ファーマシューティカルズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デュポン ファーマシューティカルズ カンパニー filed Critical デュポン ファーマシューティカルズ カンパニー
Publication of JP2002504095A publication Critical patent/JP2002504095A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP54297198A 1997-04-09 1998-04-07 Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン Pending JP2002504095A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83854097A 1997-04-09 1997-04-09
US08/838,540 1997-04-09
US7132298P 1998-01-14 1998-01-14
US60/071,322 1998-01-14
PCT/US1998/006733 WO1998045276A2 (en) 1997-04-09 1998-04-07 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinones useful as hiv reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
JP2002504095A true JP2002504095A (ja) 2002-02-05

Family

ID=26752095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54297198A Pending JP2002504095A (ja) 1997-04-09 1998-04-07 Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン

Country Status (19)

Country Link
EP (1) EP0973753A2 (zh)
JP (1) JP2002504095A (zh)
KR (1) KR20010006146A (zh)
CN (1) CN1252063A (zh)
AR (1) AR012340A1 (zh)
AU (1) AU734928B2 (zh)
BR (1) BR9808513A (zh)
CA (1) CA2284996A1 (zh)
EA (1) EA001991B1 (zh)
EE (1) EE9900452A (zh)
HR (1) HRP980143A2 (zh)
HU (1) HUP0001446A3 (zh)
IL (1) IL132188A0 (zh)
NO (1) NO314936B1 (zh)
NZ (1) NZ500592A (zh)
PL (1) PL336305A1 (zh)
SK (1) SK137899A3 (zh)
TW (1) TW587078B (zh)
WO (1) WO1998045276A2 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2322203A1 (en) * 1998-03-27 1999-10-07 Jeffrey W. Corbett 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
WO2000021565A1 (en) 1998-10-13 2000-04-20 Du Pont Pharmaceuticals Company Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent
HRP990358A2 (en) * 1998-11-19 2000-08-31 Du Pont Pharm Co Crystalline (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-3,4-dihydro-2(1h)-quinazolinone
AU1821900A (en) * 1998-11-19 2000-06-05 Du Pont Pharmaceuticals Company Process for the preparation of quinazolinones
US6175009B1 (en) 1999-11-18 2001-01-16 Dupont Pharmaceuticals Company Process for the preparation of quinazolinones
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
DE60023025T2 (de) * 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
US6555686B2 (en) * 2000-03-23 2003-04-29 Bristol-Myers Squibb Pharma Asymmetric synthesis of quinazolin-2-ones useful as HIV reverse transcriptase inhibitors
CA2403230A1 (en) * 2000-03-23 2001-09-27 Lilian A. Radesca Asymmetric synthesis of quinazolin-2-ones useful as hiv reverse transcriptase inhibitors
ZA200300255B (en) 2000-07-20 2004-09-28 Bristol Myers Squibb Pharma Co Tricyclic 2-pyridone compounds useful as HIV reverse transcriptase inhibitors.
US6596729B2 (en) * 2000-07-20 2003-07-22 Bristol-Myers Squibb Company Tricyclic-2-pyridone compounds useful as HIV reverse transcriptase inhibitors
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
WO2004060370A1 (en) * 2002-12-16 2004-07-22 Boehringer Ingelheim Pharmaceuticals, Inc. Treatment of hiv infection through combined administration of tipranavir and capravirine
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc METHOD AND APPARATUS FOR PROVIDING IMPROVED SAMPLE CAPTURING DEVICE
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc METHOD AND APPARATUS PROVIDING A VARIABLE USER INTERFACE
EP1706026B1 (en) 2003-12-31 2017-03-01 Sanofi-Aventis Deutschland GmbH Method and apparatus for improving fluidic flow and sample capture
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
EP2265324B1 (en) 2008-04-11 2015-01-28 Sanofi-Aventis Deutschland GmbH Integrated analyte measurement system
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
CN102060786A (zh) * 2011-01-20 2011-05-18 天津大学 4-(取代-1,3-二炔基)-4-(三氟甲基)-3,4-二氢取代喹唑啉-2-酮类化合物及其制备方法和应用
AP2013007166A0 (en) * 2011-04-06 2013-10-31 Univ Paris Descartes Inst De Rech Pour Le Dev Ird Pharmaceutical compositions for preventing and/or treating an HIV disease in humans
EP2855483B1 (en) 2012-05-24 2017-10-25 Novartis AG Pyrrolopyrrolidinone compounds
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
WO2014115077A1 (en) 2013-01-22 2014-07-31 Novartis Ag Substituted purinone compounds
JP6373978B2 (ja) 2013-05-27 2018-08-15 ノバルティス アーゲー イミダゾピロリジノン誘導体および疾患の処置におけるその使用
PT3004108T (pt) 2013-05-28 2018-01-24 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
JP6403761B2 (ja) 2013-05-28 2018-10-10 ノバルティス アーゲー ピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
JP2016537384A (ja) 2013-11-21 2016-12-01 ノバルティス アーゲー ピロロピロロン誘導体およびｂｅｔ阻害剤としてのその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
WO1993004047A1 (en) * 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
HUT71401A (en) * 1992-05-07 1995-11-28 Merck & Co Inc New quinazolines as inhibitors of hiv reverse transcriptase
US5663169A (en) * 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
DE4320347A1 (de) * 1993-06-19 1994-12-22 Boehringer Mannheim Gmbh Quinazolin-Derivate und diese enthaltende Arzneimittel
GB2281297A (en) * 1993-08-27 1995-03-01 Merck & Co Inc Quinazoline compounds
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
US5434152A (en) * 1993-11-08 1995-07-18 Merck & Co., Inc. Asymmetric synthesis of (S)-(-)-6-chloro-4- cyclopropyl-3,4-dihydro-4-[(2-pyridyl)ethynyl]-2(1H)-quinazolinone

Also Published As

Publication number Publication date
HRP980143A2 (en) 1999-02-28
EA001991B1 (ru) 2001-10-22
AR012340A1 (es) 2000-10-18
CA2284996A1 (en) 1998-10-15
HUP0001446A2 (hu) 2001-05-28
BR9808513A (pt) 2000-05-23
CN1252063A (zh) 2000-05-03
NO994904L (no) 1999-12-01
HUP0001446A3 (en) 2001-11-28
KR20010006146A (ko) 2001-01-26
WO1998045276A2 (en) 1998-10-15
WO1998045276A3 (en) 1999-01-14
AU734928B2 (en) 2001-06-28
EA199900907A1 (ru) 2000-04-24
PL336305A1 (en) 2000-06-19
IL132188A0 (en) 2001-03-19
EP0973753A2 (en) 2000-01-26
SK137899A3 (en) 2000-05-16
EE9900452A (et) 2000-04-17
TW587078B (en) 2004-05-11
AU6796098A (en) 1998-10-30
NZ500592A (en) 2001-09-28
NO314936B1 (no) 2003-06-16
NO994904D0 (no) 1999-10-08

Similar Documents

Publication Publication Date Title
JP2002504095A (ja) Ｈｉｖ逆転写酵素阻害剤として有用な４，４−二置換−３，４−ジヒドロ−２（１ｈ）−キナゾリノン
JP2003512375A (ja) Ｈｉｖ逆転写酵素阻害剤としての縮合ナフチリジン
US6124302A (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones useful as HIV reverse transcriptase inhibitors
US6825210B2 (en) Tricyclic compounds useful as HIV reverse transcriptase inhibitors
US6127375A (en) 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinthiones useful as HIV reverse transcriptase inhibitors
US6204262B1 (en) 1,3-Benzodiazepin-2-ones and 1,3-Benzoxazepin-2-ones useful as HIV reverse transcriptase inhibitors
US6090821A (en) Substituted quinolin-2 (1H)-ones useful as HIV reverse transcriptase inhibitors
US6946469B2 (en) Cyanamide, alkoxyamino, and urea derivatives of 4,4-disubstituted-3,4-dihydro-2(1H)-quinazolinones as HIV reverse transcriptase inhibitors
JP2002536298A (ja) Ｈｉｖプロテアーゼ阻害剤としてｎ末端置換ベンジル基を含むビス−アミノ酸スルホンアミド
EP0937067B1 (en) 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors
US20040063734A1 (en) 4,4-Disubstituted-3,4-dihydro-2 (1H)-quinazoliniones useful as HIV reverse transcriptase inhibitors
AU722489B2 (en) (4r,5s,6s,7r)-hexahydro-1- {5-(3-aminoinazole)methyl} -3-butyl-5,6-dihydr oxy-4,7-bis {phaenylmethyl} -2h-1,3-diazepin-2-one, its preparation and its use as HIV protease inhibitor
US6313110B1 (en) Substituted 2H-1,3-diazapin-2-one useful as an HIV protease inhibitor
US6218386B1 (en) A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US6462037B1 (en) 1,4-benzodiazepin-2-ones useful as HIV reverse transcriptase inhibitors
US6265406B1 (en) Substituted quinolin-2 (1H) -ones useful as HIV reverse transcriptase inhibitors
US20030220327A1 (en) Cyanamide, alkoxyamino, and urea derivatives of 1,3-benzodiazephine as HIV reverse transcriptase inhibitors
AU7371301A (en) 4,4-disubstituted-3,4-dihydro-2-)1H)- quinazolinones useful as HIV reverse transcriptase inhibitors
MXPA99004294A (en) (4r,5s,6s,7r)-hexahydro-1- [5-(3-aminoinazole)methyl]-3-butyl-5,6-dihydroxy-4,7-bis [phaenylmethyl]-2h-1,3-diazepin-2-one, its preparation and its use as hiv protease inhibitor
CZ352499A3 (cs) 4,4-Disubstituované-3,4-dihydro-2 (1H)- chinazolinony vhodné jako inhibitory HIV reverzní transkriptázy
JP2003534230A (ja) Ｈｉｖ逆転写酵素阻害剤として有用な１，３−ベンゾジアゼピン−２−オンおよび１，３−ベンゾオキサゼピン−２−オン